Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study

S. Friman, G. Tisone, F. Nevens, F. Lehner, W. Santaniello, WO. Bechstein, SV. Zhuvarel, H. Isoniemi, OO. Rummo, J. Klempnauer, S. Anaokar, M. Hurst, G. Kazeem, N. Undre, P. Trunečka

. 2021 ; 7 (8) : e722. [pub] 20210709

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024414

Background: Immunosuppression with calcineurin inhibitors (CNIs) is reportedly associated with risk of renal impairment in liver transplant recipients. It is believed that this can be mitigated by decreasing initial exposure to CNIs or delaying CNI introduction until 3-4 d posttransplantation. The ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation (DIAMOND) trial evaluated different administration strategies for prolonged-release tacrolimus (PR-T). Methods: DIAMOND was a 24-wk, open-label, phase 3b trial in de novo liver transplant recipients randomized to: PR-T 0.2 mg/kg/d (Arm 1); PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2); or PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3). In a 5-y follow-up, patients were maintained on an immunosuppressive regimen according to standard clinical practice (NCT02057484). Primary endpoint: graft survival (Kaplan-Meier analysis). Results: Follow-up study included 856 patients. Overall graft survival was 84.6% and 73.5% at 1 and 5 y post transplant, respectively. Five-year rates for Arms 1, 2, and 3 were 74.7%, 71.5%, and 74.5%, respectively. At 5 y, death-censored graft survival in the entire cohort was 74.7%. Overall graft survival in patients remaining on PR-T for ≥30 d was 79.1%. Graft survival in patients who remained on PR-T at 5 y was 87.3%. Patient survival was 86.6% at 1 y and 76.3% at 5 y, with survival rates similar in the 3 treatment arms at 5 y. Estimated glomerular filtration rate at the end of the 24-wk initial study and 5 y posttransplant was 62.1 and 61.5 mL/min/1.73 m2, respectively, and was similar between the 3 treatment arms at 5 y. Overall, 18 (2.9%) patients had ≥1 adverse drug reaction, considered possibly related to PR-T in 6 patients. Conclusions: In the DIAMOND study patient cohort, renal function, graft survival, and patient survival were similar between treatment arms at 5 y posttransplant.

000      
00000naa a2200000 a 4500
001      
bmc21024414
003      
CZ-PrNML
005      
20211013133933.0
007      
ta
008      
211006s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/TXD.0000000000001166 $2 doi
035    __
$a (PubMed)34263020
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Friman, Styrbjörn $u Transplant Institute, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
245    10
$a Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study / $c S. Friman, G. Tisone, F. Nevens, F. Lehner, W. Santaniello, WO. Bechstein, SV. Zhuvarel, H. Isoniemi, OO. Rummo, J. Klempnauer, S. Anaokar, M. Hurst, G. Kazeem, N. Undre, P. Trunečka
520    9_
$a Background: Immunosuppression with calcineurin inhibitors (CNIs) is reportedly associated with risk of renal impairment in liver transplant recipients. It is believed that this can be mitigated by decreasing initial exposure to CNIs or delaying CNI introduction until 3-4 d posttransplantation. The ADVAGRAF studied in combination with mycophenolate mofetil and basiliximab in liver transplantation (DIAMOND) trial evaluated different administration strategies for prolonged-release tacrolimus (PR-T). Methods: DIAMOND was a 24-wk, open-label, phase 3b trial in de novo liver transplant recipients randomized to: PR-T 0.2 mg/kg/d (Arm 1); PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2); or PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3). In a 5-y follow-up, patients were maintained on an immunosuppressive regimen according to standard clinical practice (NCT02057484). Primary endpoint: graft survival (Kaplan-Meier analysis). Results: Follow-up study included 856 patients. Overall graft survival was 84.6% and 73.5% at 1 and 5 y post transplant, respectively. Five-year rates for Arms 1, 2, and 3 were 74.7%, 71.5%, and 74.5%, respectively. At 5 y, death-censored graft survival in the entire cohort was 74.7%. Overall graft survival in patients remaining on PR-T for ≥30 d was 79.1%. Graft survival in patients who remained on PR-T at 5 y was 87.3%. Patient survival was 86.6% at 1 y and 76.3% at 5 y, with survival rates similar in the 3 treatment arms at 5 y. Estimated glomerular filtration rate at the end of the 24-wk initial study and 5 y posttransplant was 62.1 and 61.5 mL/min/1.73 m2, respectively, and was similar between the 3 treatment arms at 5 y. Overall, 18 (2.9%) patients had ≥1 adverse drug reaction, considered possibly related to PR-T in 6 patients. Conclusions: In the DIAMOND study patient cohort, renal function, graft survival, and patient survival were similar between treatment arms at 5 y posttransplant.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tisone, Giuseppe $u Department of Surgical Sciences, University of Rome "Tor Vergata," Rome, Italy
700    1_
$a Nevens, Frederik $u Department of Hepatology, University Hospitals KU Leuven, Leuven, Belgium
700    1_
$a Lehner, Frank $u Department of General, Visceral, and Transplantation Surgery, Hannover Medical School, Hannover, Germany
700    1_
$a Santaniello, Walter $u Unit of Hepatobiliary Surgery and Liver Transplant Center, Department of Gastroenterology and Transplantation, "A. Cardarelli" Hospital, Naples, Italy
700    1_
$a Bechstein, Wolf O $u Department of Surgery, Goethe University Hospital and Clinics, Frankfurt, Germany
700    1_
$a Zhuvarel, Sergey V $u N.V. Sklifosovsky Research Institute, Moscow, Russian Federation
700    1_
$a Isoniemi, Helena $u Department of Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Rummo, Oleg O $u Republican Scientific and Practical Center for Organ and Tissue Transplantation, Minsk, Belarus
700    1_
$a Klempnauer, Jürgen $u Department of General, Visceral, and Transplantation Surgery, Hannover Medical School, Hannover, Germany
700    1_
$a Anaokar, Swapneel $u Astellas Pharma Europe, Chertsey, United Kingdom
700    1_
$a Hurst, Martin $u Astellas Pharma Europe, Chertsey, United Kingdom
700    1_
$a Kazeem, Gbenga $u Astellas Pharma Europe, Chertsey, United Kingdom $u BENKAZ Consulting Ltd, Cambridge, United Kingdom
700    1_
$a Undre, Nasrullah $u Astellas Pharma Europe, Chertsey, United Kingdom
700    1_
$a Trunečka, Pavel $u Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00195744 $t Transplantation direct $x 2373-8731 $g Roč. 7, č. 8 (2021), s. e722
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34263020 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133930 $b ABA008
999    __
$a ind $b bmc $g 1708311 $s 1144911
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 7 $c 8 $d e722 $e 20210709 $i 2373-8731 $m Transplantation direct $n Transplant Direct $x MED00195744
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace